Definitely like the news that came out. Look forward to the new data that will be presented. http://finance.yahoo.com/news/data-amarins-amr101-presented-national-202219731.html Message in reply to:
AMRN- New Data next week-
Data for Amarin's AMR101 to be Presented at the National Lipid Association 2012 Annual Scientific Sessions
AMR101 Effects on Inflammation-Associated End Points From MARINE and ANCHOR Studies to be Featured in Poster Presentation
BEDMINSTER, N.J. and DUBLIN, Ireland, May 24, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN - News), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that additional data from the AMR101 pivotal Phase 3 studies (MARINE and ANCHOR) will be presented along with an encore presentation of the ANCHOR study by Harold E. Bays M.D., Medical Director, Louisville Metabolic and Atherosclerosis Research Center,at the National Lipid Association (NLA) 2012 Annual Scientific Sessions in Scottsdale, Ariz., on May 31- June 3.
The first poster, titled "AMR101, a Pure Ethyl Eicosapentaenoic Acid Omega-3 Fatty Acid and its Effects on Inflammation-Associated End Points from the MARINE and ANCHOR Studies," will present new data on the effects of AMR101 on inflammatory markers in patients from both Phase 3 studies.
The second poster is titled "A Phase 3, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Effect of Two Doses of AMR101 on Fasting Serum Triglycerides and Other Lipid Parameters in Statin-Treated Patients with Persistent High Triglycerides (>=200 and <500 mg/dL): The ANCHOR Study."
The MARINE study, a multicenter, placebo-controlled, randomized, double-blind, 12-week study, investigated AMR101 as a treatment for very high triglycerides (>= 500 mg/dL) in 229 patients. The ANCHOR study investigated AMR101 as a treatment for high triglycerides (>=200 and <500mg/dL) in 702 patients with mixed dyslipidemia (two or more lipid disorders) on background statin therapy who were at LDL-C (low-density lipoprotein cholesterol) goal, and who were also at high risk of cardiovascular disease. Despite the benefits of statin therapy, patients in this population have significant residual risk for cardiovascular events. The data from the ANCHOR study were previously presented at the American Heart Association in November 2011. http://finance.yahoo.com/news/data-amarins-amr101-presented-national-202219731.html